Valuation
- Market cap
- 939,000
- Revenue TTM
- $0
- Net income TTM
- $-11,230,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.99
Trading
- Volume
- 3,000
- Avg volume
- —
- Day's range
- $0.40 – $0.40
- Shares out
- 2,346,000
- Stochastic %K
- —
- Beta
- 2.19
- Analysts
- Hold
- Price target
- $600.00
Company profile
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for...
Show more
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://www.biophytis.com
- Address
- 14 avenue de l'Opéra, Paris, France
Latest news
No headlines yet.
